Pfizer Inc. (PFE), Amgen, Inc. (AMGN), Merck & Co., Inc. (MRK): Why Wouldn’t You Buy These Pharmaceutical Stocks?

Page 1 of 2

Investors are always trying to find the right balance between risk andreward. I believe the following three pharmaceutical stocks below offer a nice balance: They are expected to show some nice growth, while also paying a healthy dividend that exceeds most other investment options.

Is Pfizer Inc. (NYSE:PFE) right for you?

Dow component and pharmaceutical giant Pfizer Inc. (NYSE:PFE) is surely a juggernaut, with trailing-12-month revenue near $60 billion, and a market capitalization at approximately $200 billion. The stock has done well the past year up approximately 20% and sitting right near its $27.84 52-week high. This leads us to naturally ask is it still okay to buy Pfizer at these levels?

Pfizer Inc. (NYSE:PFE)In one word: yes. The company has blown past consensus analysts’ estimates in three of the last four quarters. It still looks relatively cheap at a 14 times trailing and 11 times forward P/E. This past year, Pfizer Inc. (NYSE:PFE) generated more than $18 billion in free cash flow, which allowed the company to raise its tasty 3.5% dividend yield yet again this past quarter. I think with the continued aging of the baby boomers creating consistent demand for the foreseeable future, a very strong balance sheet, and consistently growing and sizeable dividend, Pfizer is still a buy.

Is Amgen, Inc. (NASDAQ:AMGN) a buy at these levels?

It is no secret that Amgen, Inc. (NASDAQ:AMGN) is a world-class firm with a number of lucrative products, which have led the company to $17 billion in annual revenue and a market capitalization near $70 billion. The stock has skyrocketed nearly 40% the past 12 months, though, leaving investors wondering whether it’s still worth owning.

I believe it is, for a number of reasons. First, the company has operationally been fantastic, exceeding consensus estimates in each of the last four quarters. Second, analysts are expecting accelerating growth, from the 8% per annum it was growing the past five years to nearly 10% over the next five years. Third, the company trades at a historically cheap 16 times trailing and 11 times forward P/E.  Lastly, the company pays a consistently growing 2.2% dividend yield.  I think Amgen, Inc. (NASDAQ:AMGN) provides a great balance between growth and value , and is a solid buy for the long-term investor.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 44 percentage points in 21 months Learn how!

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!